PAVmed (PAVM) investor relations material

Executive summary

• Tangible progress across Lucid, Veris, PortIO, and Octeris, with Lucid advancing reimbursement and commercialization, Veris accelerating rollout at OSU, and PortIO achieving positive first-in-human results supporting regulatory advancement.

• Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for Q2 2026, processed 2,770 tests, and secured its first laboratory benefit manager coverage policy.

• Operating as a commercial-stage life sciences company, the group expanded its device portfolio and entered strategic partnerships, including a VA contract for EsoGuard and a partnership for Veris.

• Revenue from management fees reached $3.2M in Q2 2026, nearly flat year-over-year, while operating expenses rose to $7.1M.

• Net loss narrowed to $5.5M GAAP ($0.87/share) and $1.7M non-GAAP ($0.27/share) for Q2 2026, with EBITDA loss improving year-over-year.

Financial highlights

• Completed $30M Series D Preferred Stock offering, issued a $15M senior secured note, and raised $7.6M net proceeds after redemptions and refinancing.

• Cash and cash equivalents were $3.8M at June 30, 2026, up from $1.5M at year-end 2025, but down from $6.5M in Q1 2026.

• Equity method investment in Lucid valued at $33M, reflecting 31.3M shares at $1.07 per share.

• Senior secured convertible notes increased to $15.1M from $14.9M.

• Revenue for Q2 2026 was $33,000, compared to $6,000 in Q2 2025.

Outlook and guidance

• Confident in securing positive Medicare draft coverage for Lucid; Veris targets early 2027 for FDA 510(k) submission for its implantable monitor.

• PortIO expects to submit an FDA pre-submission meeting request in Q4 2026, potentially shifting regulatory pathway to 510K.

• Management expects recurring losses and negative cash flows to continue, with substantial doubt about going concern status without additional capital.